Pulse Brain · Growing Health Evidence Index
Peer-reviewed

The Anti-atherogenic Activity of Beauveriolide Derivative BVD327, a Sterol <i>O</i>-Acyltransferase 2-Selective Inhibitor, in Apolipoprotein E Knockout Mice

Taichi Ohshiro, Satoshi Imuta, Ichiro Hijikuro, Hiroaki Yagyu, Takashi Takahashi, Takayuki Doi, Shun Ishibashi, Hiroshi Tomoda

Biological and Pharmaceutical Bulletin · 2020

Read source ↗ All evidence

Summary

The fungal 13-membered cyclodepsipeptides, beauveriolides I and III, were previously reported to be atheroprotective activity in mouse models via inhibiting sterol O-acyltransferase (SOAT) activity. A total of 149 beauveriolide derivatives (BVDs) synthesized combinatorially were evaluated in in silico absorption, distribution, metabolism and excretion (ADME) analysis and inhibitory activity toward the two SOAT isozymes, SOAT1 and SOAT2. Hence, only 11 BVDs exhibited SOAT2-selective inhibition. Among these, we chose BVD327, which had the highest ADME score, for further evaluation. BVD327 administration (50 mg/kg/d, per os (p.o.)) significantly decreased atherosclerotic lesions in the aorta and heart (25.4 ± 6.9 and 20.6 ± 2.9%, respectively) in apolipoprotein E knockout (Apoe<sup>-/-</sup>)

Source type
Peer-reviewed study
DOI
10.1248/bpb.b19-00913
Catalogue ID
BFmoakvgtk-7e0mcq
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.